JP2016513717A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016513717A5 JP2016513717A5 JP2016502662A JP2016502662A JP2016513717A5 JP 2016513717 A5 JP2016513717 A5 JP 2016513717A5 JP 2016502662 A JP2016502662 A JP 2016502662A JP 2016502662 A JP2016502662 A JP 2016502662A JP 2016513717 A5 JP2016513717 A5 JP 2016513717A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- disorder
- trpc5
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 claims 10
- 102000003621 TRPC5 Human genes 0.000 claims 7
- 101700005591 TRPC5 Proteins 0.000 claims 7
- 230000001404 mediated Effects 0.000 claims 7
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 239000011780 sodium chloride Substances 0.000 claims 4
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 3
- 206010015037 Epilepsy Diseases 0.000 claims 3
- 208000001083 Kidney Disease Diseases 0.000 claims 3
- 206010029149 Nephropathy Diseases 0.000 claims 3
- 206010029151 Nephropathy Diseases 0.000 claims 3
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 3
- 125000004737 (C1-C6) haloalkoxy group Chemical group 0.000 claims 2
- 230000000202 analgesic Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 125000006716 (C1-C6) heteroalkyl group Chemical group 0.000 claims 1
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-Aminophenol Chemical class NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 claims 1
- LZNWYQJJBLGYLT-UHFFFAOYSA-N 4-hydroxy-2-methyl-1,1-dioxo-N-pyridin-2-ylthieno[2,3-e]thiazine-3-carboxamide Chemical compound OC=1C=2SC=CC=2S(=O)(=O)N(C)C=1C(=O)NC1=CC=CC=N1 LZNWYQJJBLGYLT-UHFFFAOYSA-N 0.000 claims 1
- ZWJINEZUASEZBH-UHFFFAOYSA-N Fenamic acid Chemical class OC(=O)C1=CC=CC=C1NC1=CC=CC=C1 ZWJINEZUASEZBH-UHFFFAOYSA-N 0.000 claims 1
- 230000001430 anti-depressive Effects 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940121363 anti-inflammatory agents Drugs 0.000 claims 1
- 239000001961 anticonvulsive agent Substances 0.000 claims 1
- 239000000935 antidepressant agent Substances 0.000 claims 1
- 239000002282 antimigraine agent Substances 0.000 claims 1
- 239000002249 anxiolytic agent Substances 0.000 claims 1
- 125000004104 aryloxy group Chemical group 0.000 claims 1
- 229940079593 drugs Drugs 0.000 claims 1
- 239000003862 glucocorticoid Substances 0.000 claims 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drugs Drugs 0.000 claims 1
- 230000003364 opioid Effects 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- 150000005599 propionic acid derivatives Chemical class 0.000 claims 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 claims 1
- 229960001860 salicylate Drugs 0.000 claims 1
Claims (11)
- 式(III):
R2は、1〜3個のR6で置換されたC1-C6アルコキシまたは1〜3個のR6で置換されたC6-C10アリールオキシであり;
R3は、C2-C6ヒドロキシアルキルまたはC1-C6ヘテロアルキルであり;
R4は、C1-C6アルキルであり;
R6は、独立してC1-C6アルキル、ハロ、C1-C6ハロアルキル、C1-C6ハロアルコキシ、またはC1-C6アルコキシでありする
R8は、独立してC1-C6アルキル、ハロ、C1-C6ハロアルキル、C1-C6ハロアルコキシ、またはC1-C6アルコキシであり;
各Raは、C1-C6アルキル、C1-C6ハロアルキルまたはハロであり;
nは、1または2であり;そして
mは、1、2、または3である]
で示される化合物、またはそれらの医薬的に許容し得る塩。 - 請求項1〜3のいずれか1項に記載の化合物またはその医薬的に許容される塩を含む医薬組成物。
- TRPC5介在障害を処置するための請求項4記載の医薬組成物。
- TRPC5介在障害が、神経精神障害、神経変性障害、腎症、および発作性障害からなる群より選択される、請求項5記載の医薬組成物。
- TRPC5介在障害を処置するための医薬の製造における、請求項1〜3のいずれか1項に記載の化合物または請求項4〜6のいずれか1項に記載の医薬組成物の使用。
- TRPC5介在障害が、神経精神障害、神経変性障害、腎症、および発作性障害からなる群より選択される、TRPC5介在障害を処置するための医薬の製造における、請求項1〜3のいずれか1項に記載の化合物または請求項4〜6のいずれか1項に記載の医薬組成物の使用。
- 請求項1〜3のいずれか1項に記載の化合物またはその医薬的に許容される塩と、鎮痛剤、抗うつ剤、抗不安剤、抗てんかん剤、抗炎症剤、および抗片頭痛剤からなる群より選択される1つ以上の他の医薬的に活性な薬物との組み合わせを含む、TRPC5介在障害を処置するための剤。
- 該鎮痛剤が、オピオイド、グルココルチコステロイド、非ステロイド性抗炎症薬、ナフチルアルカノン、オキシカム、パラ-アミノフェノール誘導体、プロピオン酸、プロピオン酸誘導体、サリチレート、フェナメート、フェナム酸誘導体、ピロゾール、およびピロゾール誘導体を含む、請求項9記載の剤。
- TRPC5介在障害が、神経精神障害、神経変性障害、腎症、および発作性障害からなる群より選択される、請求項9または10に記載の剤。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361789724P | 2013-03-15 | 2013-03-15 | |
US61/789,724 | 2013-03-15 | ||
PCT/US2014/027920 WO2014143799A2 (en) | 2013-03-15 | 2014-03-14 | Substituted xanthines and methods of use thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2016513717A JP2016513717A (ja) | 2016-05-16 |
JP2016513717A5 true JP2016513717A5 (ja) | 2017-04-20 |
JP6360149B2 JP6360149B2 (ja) | 2018-07-18 |
Family
ID=50680155
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016502662A Active JP6360149B2 (ja) | 2013-03-15 | 2014-03-14 | 置換キサンチンおよびその使用方法 |
Country Status (32)
Country | Link |
---|---|
US (6) | US9359359B2 (ja) |
EP (1) | EP2970303B3 (ja) |
JP (1) | JP6360149B2 (ja) |
KR (1) | KR102227629B1 (ja) |
CN (2) | CN107082782B (ja) |
AU (1) | AU2014228206C1 (ja) |
CA (1) | CA2899646C (ja) |
CL (1) | CL2015002738A1 (ja) |
CY (1) | CY1119042T1 (ja) |
DK (1) | DK2970303T6 (ja) |
EA (1) | EA028815B1 (ja) |
ES (1) | ES2636835T7 (ja) |
HK (1) | HK1217329A1 (ja) |
HR (1) | HRP20170840T4 (ja) |
HU (1) | HUE033528T4 (ja) |
IL (1) | IL240216B (ja) |
LT (1) | LT2970303T (ja) |
MX (1) | MX370372B (ja) |
MY (1) | MY189912A (ja) |
NZ (1) | NZ711718A (ja) |
PE (1) | PE20151779A1 (ja) |
PH (1) | PH12015502141A1 (ja) |
PL (1) | PL2970303T6 (ja) |
PT (1) | PT2970303T (ja) |
RS (1) | RS56066B2 (ja) |
SG (1) | SG11201506479TA (ja) |
SI (1) | SI2970303T1 (ja) |
TW (1) | TWI609867B (ja) |
UA (1) | UA117470C2 (ja) |
UY (1) | UY35488A (ja) |
WO (1) | WO2014143799A2 (ja) |
ZA (1) | ZA201505414B (ja) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8173750B2 (en) | 2009-04-23 | 2012-05-08 | ATRP Solutions, Inc. | Star macromolecules for personal and home care |
AU2014228206C1 (en) | 2013-03-15 | 2018-10-25 | Hydra Biosciences, Llc | Substituted xanthines and methods of use thereof |
JP6667092B2 (ja) * | 2014-08-11 | 2020-03-18 | ハイドラ・バイオサイエンシーズ・リミテッド・ライアビリティ・カンパニーHydra Biosciences, LLC | ピロロ[3,2−d]ピリミジン−2,4(3H,5H)−ジオン誘導体 |
WO2016159747A1 (en) | 2015-03-27 | 2016-10-06 | Latvian Institute Of Organic Synthesis | Ethynylxanthines, preparation and use as calcium ion channel modulators |
WO2016159746A1 (en) | 2015-03-27 | 2016-10-06 | Latvian Institute Of Organic Synthesis | Novel ethynylxanthines, their preparation and use as inhibitors of matrix metalloproteinases and angiogenesis |
CA2989161C (en) | 2015-03-27 | 2022-03-01 | Latvian Institute Of Organic Synthesis | Ethynylxanthines, preparation and use for cancer treatment |
BR112017021386A2 (pt) * | 2015-04-08 | 2018-07-03 | Lewis And Clark Pharmaceuticals, Inc. | carbamatos de alquinila com xantina substituída/carbamatos reversos como antagonistas de a2b. |
CN107118586A (zh) * | 2016-02-24 | 2017-09-01 | 中国科学技术大学 | 含氮杂环基取代的烯类化合物的用途 |
GB201702160D0 (en) * | 2017-02-09 | 2017-03-29 | Univ Leeds Innovations Ltd | Inhibitors for use in therapy |
WO2018157800A1 (en) * | 2017-02-28 | 2018-09-07 | National Institute Of Biological Sciences, Beijing | Mlkl inhibitors |
US11666577B2 (en) * | 2017-02-28 | 2023-06-06 | National Institute Of Biological Sciences, Beijing | MLKL inhibitors |
CN110997675B (zh) * | 2017-07-11 | 2022-06-07 | 勃林格殷格翰国际公司 | 新的取代的黄嘌呤衍生物 |
WO2019173327A1 (en) | 2018-03-05 | 2019-09-12 | Goldfinch Bio, Inc. | Imidazodiazepinediones and methods of use thereof |
DK3894410T3 (da) * | 2018-12-12 | 2023-11-27 | Boehringer Ingelheim Int | Substituerede xanthinderivater |
JP7408662B2 (ja) | 2018-12-12 | 2024-01-05 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換キサンタン誘導体 |
CN112979651B (zh) * | 2021-04-09 | 2022-02-01 | 南京纽邦生物科技有限公司 | 一种副黄嘌呤的制备方法 |
CN113354646B (zh) * | 2021-07-06 | 2022-11-15 | 南开大学 | 8-芳氧基烷氧基取代黄嘌呤衍生物及其制备方法和应用 |
CN115636831A (zh) * | 2022-10-27 | 2023-01-24 | 中国药科大学 | 稠合嘧啶二酮类化合物、其用途以及药物组合物 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4304650A1 (de) * | 1993-02-16 | 1994-08-18 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel |
US6878715B1 (en) * | 1994-02-18 | 2005-04-12 | Cell Therapeutics, Inc. | Therapeutic compounds for inhibiting interleukin-12 signals and method for using same |
JP4191269B2 (ja) | 1996-05-17 | 2008-12-03 | 興和株式会社 | 新規なアニリド化合物及びこれを含有する医薬 |
JPH10318487A (ja) | 1997-05-16 | 1998-12-04 | Mitsubishi Gas Chem Co Inc | 真空断熱材用ゲッタ |
US6075029A (en) | 1998-01-02 | 2000-06-13 | Cell Therapeutics, Inc. | Xanthine modulators of metabolism of cellular P-450 |
US6187780B1 (en) * | 1998-04-16 | 2001-02-13 | Boehringer Ingelheim Pharma Kg | Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity |
MXPA01010143A (es) * | 1999-04-09 | 2003-07-14 | Cell Therapeutics Inc | Derivados de xantina y analogos como inhibidores de transmision de senales celulares. |
KR20030014394A (ko) * | 2000-07-04 | 2003-02-17 | 노보 노르디스크 에이/에스 | 효소 dpp-iv의 억제제인 헤테로고리 화합물 |
CN1486302A (zh) | 2000-12-07 | 2004-03-31 | CV���ƹ�˾ | 作为抗冠状动脉疾病或动脉硬化的abca-1加强化合物的取代1,3,5-三嗪和嘧啶 |
ES2282386T3 (es) * | 2001-02-24 | 2007-10-16 | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG | Derivados de xantina, su preparacion y su uso como medicamentos. |
KR100937620B1 (ko) * | 2001-11-09 | 2010-01-20 | 씨브이 쎄러퓨틱스, 인코포레이티드 | A2b 아데노신 수용체 길항제 |
ATE403656T1 (de) * | 2003-05-06 | 2008-08-15 | Cv Therapeutics Inc | Xanthinderivate als a2b- adenosinrezeptorantagonisten |
EP1691891A2 (en) | 2003-11-13 | 2006-08-23 | The Board Of Regents, The University Of Texas System | Inhibition of trp channels as a treatment for cardiac hypertrophy and heart failure |
EP1841448A2 (en) | 2004-12-30 | 2007-10-10 | Diakine Therapeutics, Inc. | Pharmaceutical compositions and methods for restoring beta-cell mass and function |
WO2006089168A2 (en) | 2005-02-18 | 2006-08-24 | Cornell Research Foundation, Inc. | Methods for modulating ion channels |
TW200800217A (en) * | 2005-08-10 | 2008-01-01 | Smithkline Beecham Corp | Novel compounds |
DE602006012694D1 (de) | 2005-09-06 | 2010-04-15 | Glaxosmithkline Llc | Benzimidazolthiophenverbindungen als plk-modulatoren |
JP2009518333A (ja) * | 2005-12-07 | 2009-05-07 | ユセベ ファルマ ソシエテ アノニム | キサンチン誘導体、その調製方法及びその使用 |
CN101384261B (zh) * | 2005-12-22 | 2011-12-07 | 海德拉生物科学公司 | 治疗疼痛的组合物 |
CA2637674A1 (en) | 2006-01-19 | 2007-07-26 | Abbott Laboratories | 2-imino-benzimidazoles |
WO2007101213A2 (en) | 2006-02-28 | 2007-09-07 | Kalypsys, Inc. | Novel 2-oxo-1,2,3,4-tetrahydropyrimidines, bicyclic pyrimidine diones and imidazolidine-2,4-diones useful as inducible nitric oxide synthase inhibitors |
WO2008011518A2 (en) | 2006-07-19 | 2008-01-24 | Diakine Therapeutics, Inc. | Encapsulation system |
WO2009157938A1 (en) * | 2008-06-26 | 2009-12-30 | Cv Therapeutics, Inc. | A2b adenosine receptor antagonists for treating cancer |
WO2011022638A1 (en) | 2009-08-20 | 2011-02-24 | Transposagen Biopharmaceuticals, Inc. | Trp inhibitors and uses thereof |
WO2011114184A1 (en) * | 2010-03-15 | 2011-09-22 | Glenmark Pharmaceuticals S.A. | Amides of heterocyclic compounds as trpa1 inhibitors |
WO2012050641A2 (en) | 2010-06-08 | 2012-04-19 | Hydra Biosciences, Inc | Use of trpa1 antagonists to prevent or treat infections caused by biological-warfare agents |
JP2013023102A (ja) | 2011-07-22 | 2013-02-04 | Panasonic Corp | 列車情報提供システム |
TW201311690A (zh) * | 2011-08-09 | 2013-03-16 | Hydra Biosciences Inc | 抑制暫態受體電位離子通道trpa1 |
CN103121970B (zh) | 2012-12-04 | 2015-04-29 | 中国科学院昆明植物研究所 | 苯并咪唑及其衍生物,其药物组合物及其在制备抗抑郁药物中的应用 |
AU2014228206C1 (en) | 2013-03-15 | 2018-10-25 | Hydra Biosciences, Llc | Substituted xanthines and methods of use thereof |
-
2014
- 2014-03-14 AU AU2014228206A patent/AU2014228206C1/en active Active
- 2014-03-14 DK DK14722452.1T patent/DK2970303T6/en active
- 2014-03-14 EA EA201591615A patent/EA028815B1/ru not_active IP Right Cessation
- 2014-03-14 RS RS20170566A patent/RS56066B2/sr unknown
- 2014-03-14 CN CN201710063554.XA patent/CN107082782B/zh active Active
- 2014-03-14 NZ NZ711718A patent/NZ711718A/en unknown
- 2014-03-14 ES ES14722452.1T patent/ES2636835T7/es active Active
- 2014-03-14 UA UAA201507774A patent/UA117470C2/uk unknown
- 2014-03-14 HU HUE14722452A patent/HUE033528T4/en unknown
- 2014-03-14 LT LTEP14722452.1T patent/LT2970303T/lt unknown
- 2014-03-14 PL PL14722452T patent/PL2970303T6/pl unknown
- 2014-03-14 TW TW103109651A patent/TWI609867B/zh active
- 2014-03-14 PE PE2015001829A patent/PE20151779A1/es active IP Right Grant
- 2014-03-14 MX MX2015011617A patent/MX370372B/es active IP Right Grant
- 2014-03-14 KR KR1020157029667A patent/KR102227629B1/ko active IP Right Grant
- 2014-03-14 SI SI201430241T patent/SI2970303T1/sl unknown
- 2014-03-14 SG SG11201506479TA patent/SG11201506479TA/en unknown
- 2014-03-14 JP JP2016502662A patent/JP6360149B2/ja active Active
- 2014-03-14 PT PT147224521T patent/PT2970303T/pt unknown
- 2014-03-14 US US14/210,781 patent/US9359359B2/en active Active
- 2014-03-14 CN CN201480023267.0A patent/CN105143229B/zh active Active
- 2014-03-14 MY MYPI2015702631A patent/MY189912A/en unknown
- 2014-03-14 WO PCT/US2014/027920 patent/WO2014143799A2/en active Application Filing
- 2014-03-14 CA CA2899646A patent/CA2899646C/en active Active
- 2014-03-14 EP EP14722452.1A patent/EP2970303B3/en active Active
- 2014-03-17 UY UY0001035488A patent/UY35488A/es active IP Right Grant
-
2015
- 2015-07-28 ZA ZA2015/05414A patent/ZA201505414B/en unknown
- 2015-07-29 IL IL240216A patent/IL240216B/en active IP Right Grant
- 2015-09-15 PH PH12015502141A patent/PH12015502141A1/en unknown
- 2015-09-15 CL CL2015002738A patent/CL2015002738A1/es unknown
-
2016
- 2016-04-25 US US15/137,327 patent/US20160237089A1/en not_active Abandoned
- 2016-05-10 HK HK16105298.0A patent/HK1217329A1/zh unknown
-
2017
- 2017-06-01 HR HRP20170840TT patent/HRP20170840T4/hr unknown
- 2017-06-14 US US15/622,838 patent/US9969736B2/en active Active
- 2017-06-20 CY CY20171100647T patent/CY1119042T1/el unknown
-
2018
- 2018-05-02 US US15/968,941 patent/US10399982B2/en active Active
-
2019
- 2019-04-29 US US16/397,697 patent/US11208409B2/en active Active
-
2021
- 2021-11-10 US US17/523,838 patent/US11958854B2/en active Active
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2016513717A5 (ja) | ||
JP2016528301A5 (ja) | ||
JP2017505285A5 (ja) | ||
CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
JP2016513687A5 (ja) | ||
JP2014221779A5 (ja) | ||
JP2013519675A5 (ja) | ||
MY194087A (en) | Use of gabaa receptor reinforcing agent in preparation of sedative and anesthetic medicament | |
EP4227304A3 (en) | Thiadiazole analogs and their use for treating diseases associated with a deficiency of smn motor neurons | |
JP2016518337A5 (ja) | ||
MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
IN2013MU03577A (ja) | ||
JP2016537338A5 (ja) | ||
EA201692298A1 (ru) | Производные карбоксамидов | |
UY36124A (es) | Derivados de carboxamida | |
EA201890532A1 (ru) | Новые аннелированные бензамиды | |
MA40781A (fr) | Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale | |
JP2016515550A5 (ja) | ||
AR058109A1 (es) | Acido 3 - (4 - {[4 -(4 -{[3 - (3, 3 - dimetil - 1 - piperidinil)propil]oxi}fenil) - 1 - piperidinil]carbonil} - 1 - naftalenil)propanoico como antagonistas de los receptotres de histamina h1/h3, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamie | |
AR099943A1 (es) | Derivados quirales de ácido ciclopentancarboxílico 2,5-disustituidos y su uso | |
JOP20190054B1 (ar) | مركبات إندازول للاستخدام في إصابات الأوتار و/ أو الرباط | |
TH167758B (th) | อนุพันธ์อะซาอินโดลอะซิติกแอซิดและการใช้อนุพันธ์ดังกล่าว เป็นสารควบคุมตัวรับพรอสตาแกลนดิน d2 | |
TH1701002063A (th) | ตัวยับยั้งแอลโดสเทอโรนซินเธส | |
AR111478A1 (es) | Gemcabeno, sus sales farmacéuticamente aceptables, composiciones y métodos de uso | |
TH165228A (th) | อนุพันธ์เอไมด์ สำหรับ gpr119 อะโกนิสต์ |